Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

Tsourdi, E
Zillikens, M.C.
Meier, C
Body, JJ
Rodriguez, EG
Anastasilakis, AD
Abrahamsen, B
McCloskey, E
Hofbauer, LC
Guanabens, N
Obermayer-Pietsch, B
Ralston, SH
Eastell, R
Pepe, J
Palermo, A
Langdahl, B

January 2021

Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension.

Papapoulos, S.
Chapurlat, R.
Libanati, C.
Brandi, M.
Brown, J.
Czerwinski, E.
Krieg, M. A.
Man, Z.
Mellstrom, D.
Radominski, S.
Reginster, Jean-Yves
Resch, H.
Roman, J.
Roux, C.
Vittinghoff, E.
Austin, M.
Daizadeh, N.
Bradley, M.
Grauer, A.
Cummings, S.
Bone, H.

March 2012

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...

Effect of denosumab treatment on the risk of fractures in subgroupsof women with postmenopausal osteoporosis

McClung, Michael R.
Boonen, Steven
Torring, Ove
Roux, Christian
Rizzoli, Rene
Bone, Henry G.
Benhamou, Claude-Laurent
Lems, Willem F.
Minisola, Salvatore
Halse, Johan
Hoeck, Hans C.
Eastell, Richard
Wang, Andrea
Siddhanti, Suresh
Cummings, Steven R.

January 2012

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3years

Ferrari, S.
Adachi, J.
Lippuner, K.
Zapalowski, C.
Miller, P.
Reginster, J.-Y
Törring, O.
Kendler, D.
Daizadeh, N.
Wang, A.
O'Malley, C.
Wagman, R.
Libanati, C.
Lewiecki, E.

October 2021

Summary: Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Ferrari, S
Adachi, J D
Lippuner, Kurt
Zapalowski, C
Miller, P D
Reginster, J-Y
Törring, O
Kendler, D L
Daizadeh, N S
Wang, A
O'Malley, C D
Wagman, R B
Libanati, C
Lewiecki, E M

December 2015

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmeno...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

FERRARI, S.
ADACHI, J.D.
LUPPUNER, K.
ZAPALOWSKI, C.
MILLER, P.D.
Reginster, Jean-Yves
TORRING, O.
KENDLER, D.L.
DAIZADEH, N.S.
WANG, A.
O'MALLEY, C.D.
WAGMAN, R.B.
LIBANATI, C.
LEWICKI, E.M.

January 2015

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmen...

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in

Christopher Recknor
Matt Austin
Andrea Wang
Andreas Grauer
Rachel B Wagman

August 2016

Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ens...

Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

Siris, Ethel
McDermott, Michele
Pannacciulli, Nicola
Miller, Paul D.
Lewiecki, E. Michael
Chapurlat, Roland
Jódar Gimeno, José Esteban
Huang, Shuang
Kanis, John A.

January 2020

The 3-year placebo-controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Ev...

Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed

Ferrari, Serge Livio
Lewiecki, E. Michael
Butler, Peter W.
Kendler, David L.
Napoli, Nicola
Huang, Shuang
Crittenden, Daria B.
Pannacciulli, Nicola
Siris, Ethel
Binkley, Neil

January 2020

Antiresorptive therapies reduce fracture risk; however, long-term bone turnover inhibition may raise...

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.

Kendler, D L
Chines, A
Brandi, M L
Papapoulos, S
Lewiecki, E M
Reginster, J-Y
Muñoz Torres, M
Wang, A
Bone, H G

September 2018

This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate...

Western osteoporosis alliance clinical practice series: Evaluating the balance of benefits and risks of long-term osteoporosis therapies

Hanley, David A.
McClung, Michael R.
Davison, K. Shawn
Dian, Larry
Harris, Steve T.
Miller, Paul D.
Lewiecki, E. Michael
Kendler, David L.

January 2017

Osteoporosis is a chronic disease that requires life-long strategies to reduce fracture risk. Few tr...

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

Michael R. Mcclung
Steven Boonen
Ove Torring
Christian Roux
Rene Rizzoli
Henry G. Bone
Claude-Laurent Benhamou
Willem F. Lems
Salvatore Minisola
Johan Halse
Hans C. Hoeck
Richard Eastell
Andrea Wang
Suresh Siddhanti
Steven R. Cummings

January 2012

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...

ORIGINAL ARTICLE

August 2016

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM o...

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Kendler, D.L.
Chines, A.
Brandi, M.L.
Papapoulos,
Lewiecki, E.M.
Reginster, Jean-Yves
Munoz Torres, M.
Wang, A.
Bone, H.G.

January 2019

Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates i...

Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial

ADAMI, Silvano
Libanati, Cesar
Boonen, Steven
Cummings, Steven R
Ho, Pei Ran
Wang, Andrea
Siris, Ethel
Lane, Joseph
Adachi, Jonathan D
Bhandari, Mohit
de Gregorio, Luiz
Gilchrist, Nigel
Lyritis, George
Möller, Gerd
Palacios, Santiago
Pavelka, Karel
Heinrich, Resch
Roux, Christian
Uebelhart, Daniel

January 2012

Fracture is the major complication of osteoporosis, and it allows the identification of individuals ...

Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

Tsourdi, E
Zillikens, M.C.
Meier, C
Body, JJ
Rodriguez, EG
Anastasilakis, AD
Abrahamsen, B
McCloskey, E
Hofbauer, LC
Guanabens, N
Obermayer-Pietsch, B
Ralston, SH
Eastell, R
Pepe, J
Palermo, A
Langdahl, B

January 2021

Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension.

Papapoulos, S.
Chapurlat, R.
Libanati, C.
Brandi, M.
Brown, J.
Czerwinski, E.
Krieg, M. A.
Man, Z.
Mellstrom, D.
Radominski, S.
Reginster, Jean-Yves
Resch, H.
Roman, J.
Roux, C.
Vittinghoff, E.
Austin, M.
Daizadeh, N.
Bradley, M.
Grauer, A.
Cummings, S.
Bone, H.

March 2012

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...

Effect of denosumab treatment on the risk of fractures in subgroupsof women with postmenopausal osteoporosis

McClung, Michael R.
Boonen, Steven
Torring, Ove
Roux, Christian
Rizzoli, Rene
Bone, Henry G.
Benhamou, Claude-Laurent
Lems, Willem F.
Minisola, Salvatore
Halse, Johan
Hoeck, Hans C.
Eastell, Richard
Wang, Andrea
Siddhanti, Suresh
Cummings, Steven R.

January 2012

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3years

Ferrari, S.
Adachi, J.
Lippuner, K.
Zapalowski, C.
Miller, P.
Reginster, J.-Y
Törring, O.
Kendler, D.
Daizadeh, N.
Wang, A.
O'Malley, C.
Wagman, R.
Libanati, C.
Lewiecki, E.

October 2021

Summary: Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Ferrari, S
Adachi, J D
Lippuner, Kurt
Zapalowski, C
Miller, P D
Reginster, J-Y
Törring, O
Kendler, D L
Daizadeh, N S
Wang, A
O'Malley, C D
Wagman, R B
Libanati, C
Lewiecki, E M

December 2015

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmeno...

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

FERRARI, S.
ADACHI, J.D.
LUPPUNER, K.
ZAPALOWSKI, C.
MILLER, P.D.
Reginster, Jean-Yves
TORRING, O.
KENDLER, D.L.
DAIZADEH, N.S.
WANG, A.
O'MALLEY, C.D.
WAGMAN, R.B.
LIBANATI, C.
LEWICKI, E.M.

January 2015

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmen...

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in

Christopher Recknor
Matt Austin
Andrea Wang
Andreas Grauer
Rachel B Wagman

August 2016

Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ens...

Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

Siris, Ethel
McDermott, Michele
Pannacciulli, Nicola
Miller, Paul D.
Lewiecki, E. Michael
Chapurlat, Roland
Jódar Gimeno, José Esteban
Huang, Shuang
Kanis, John A.

January 2020

The 3-year placebo-controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Ev...

Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed

Ferrari, Serge Livio
Lewiecki, E. Michael
Butler, Peter W.
Kendler, David L.
Napoli, Nicola
Huang, Shuang
Crittenden, Daria B.
Pannacciulli, Nicola
Siris, Ethel
Binkley, Neil

January 2020

Antiresorptive therapies reduce fracture risk; however, long-term bone turnover inhibition may raise...

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.

Kendler, D L
Chines, A
Brandi, M L
Papapoulos, S
Lewiecki, E M
Reginster, J-Y
Muñoz Torres, M
Wang, A
Bone, H G

September 2018

This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate...

Western osteoporosis alliance clinical practice series: Evaluating the balance of benefits and risks of long-term osteoporosis therapies

Hanley, David A.
McClung, Michael R.
Davison, K. Shawn
Dian, Larry
Harris, Steve T.
Miller, Paul D.
Lewiecki, E. Michael
Kendler, David L.

January 2017

Osteoporosis is a chronic disease that requires life-long strategies to reduce fracture risk. Few tr...

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

Michael R. Mcclung
Steven Boonen
Ove Torring
Christian Roux
Rene Rizzoli
Henry G. Bone
Claude-Laurent Benhamou
Willem F. Lems
Salvatore Minisola
Johan Halse
Hans C. Hoeck
Richard Eastell
Andrea Wang
Suresh Siddhanti
Steven R. Cummings

January 2012

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...

ORIGINAL ARTICLE

August 2016

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM o...

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Kendler, D.L.
Chines, A.
Brandi, M.L.
Papapoulos,
Lewiecki, E.M.
Reginster, Jean-Yves
Munoz Torres, M.
Wang, A.
Bone, H.G.

January 2019

Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates i...

Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial

ADAMI, Silvano
Libanati, Cesar
Boonen, Steven
Cummings, Steven R
Ho, Pei Ran
Wang, Andrea
Siris, Ethel
Lane, Joseph
Adachi, Jonathan D
Bhandari, Mohit
de Gregorio, Luiz
Gilchrist, Nigel
Lyritis, George
Möller, Gerd
Palacios, Santiago
Pavelka, Karel
Heinrich, Resch
Roux, Christian
Uebelhart, Daniel

January 2012

Fracture is the major complication of osteoporosis, and it allows the identification of individuals ...

Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

Tsourdi, E
Zillikens, M.C.
Meier, C
Body, JJ
Rodriguez, EG
Anastasilakis, AD
Abrahamsen, B
McCloskey, E
Hofbauer, LC
Guanabens, N
Obermayer-Pietsch, B
Ralston, SH
Eastell, R
Pepe, J
Palermo, A
Langdahl, B

January 2021

Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension.

Papapoulos, S.
Chapurlat, R.
Libanati, C.
Brandi, M.
Brown, J.
Czerwinski, E.
Krieg, M. A.
Man, Z.
Mellstrom, D.
Radominski, S.
Reginster, Jean-Yves
Resch, H.
Roman, J.
Roux, C.
Vittinghoff, E.
Austin, M.
Daizadeh, N.
Bradley, M.
Grauer, A.
Cummings, S.
Bone, H.

March 2012

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...

Effect of denosumab treatment on the risk of fractures in subgroupsof women with postmenopausal osteoporosis

McClung, Michael R.
Boonen, Steven
Torring, Ove
Roux, Christian
Rizzoli, Rene
Bone, Henry G.
Benhamou, Claude-Laurent
Lems, Willem F.
Minisola, Salvatore
Halse, Johan
Hoeck, Hans C.
Eastell, Richard
Wang, Andrea
Siddhanti, Suresh
Cummings, Steven R.

January 2012

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Abstract

Extracted data

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Abstract

Extracted data

Related items

Related items